The thing that matters most when you pick a GLP-1 telehealth provider is not the brand name. It’s pharmacy transparency. Where is your medication compounded, who is checking it, and can you verify any of that before you hand over a credit card?
I went through five providers, read their fine print, compared cash prices, and checked pharmacy credentials. Here is what I found.
*Quick note before we get into it: compounded GLP-1 medications are not FDA-approved finished drug products, and individual results with any weight-loss medication will vary. This is informational, not medical advice.*
1. HealthRX
Best for: Cash-pay buyers who want named-pharmacy accountability at the lowest entry price
Compounded semaglutide starts at $99 a month and tirzepatide at $149. Those are among the lowest cash prices I found anywhere, and they hold up when you read the terms because there are no hidden enrollment fees tacked on. The medication is dispensed by Manifest Pharmacy in Greer, South Carolina, a 503A compounding pharmacy operating under USP-797 standards with lot-level tracking from bench to shipment. That is not boilerplate. Being able to name a specific pharmacy, a specific location, and a specific compliance standard is genuinely rare in this category. Manifest is also LegitScript-certified (cert 50087439). Physician review runs about 24 hours, and overnight shipping is free to all 50 states.
The trial data HealthRX points to is from the actual clinical studies: roughly 15% body weight reduction with semaglutide at 68 weeks (STEP 1) and roughly 21% with tirzepatide at 72 weeks (SURMOUNT-1). Those are trial figures, not the platform’s own claims.
Pro: Named 503A pharmacy, free overnight shipping, lowest compounded prices I saw
Con: Compounded meds are not FDA-approved finished products, which is true of most cash-pay GLP-1 options right now
2. Mochi Health
Best for: People who want obesity-medicine clinicians and more hands-on monitoring
Mochi puts board-certified obesity-medicine doctors on your care team, not just a general practitioner doing a quick async review. Monthly cash pricing on compounded semaglutide sits near $99 and tirzepatide near $199. The monitoring cadence is more involved than most telehealth-only setups, which some people genuinely want and others find unnecessary. If you are managing comorbidities alongside weight loss, the clinical depth here is worth the slightly higher tirzepatide price.
Pro: Obesity-medicine specialists, not generalists
Con: Tirzepatide pricing is higher than some alternatives at the same compounded tier
3. FormBlends
Best for: Buyers who want published purity data on their compounded GLP-1, or who want GLP-1s alongside a peptide catalog
FormBlends operates a compounded GLP-1 program with physician oversight and dispenses through an FDA-registered 503A pharmacy. The part that stands out is the published per-product testing: HPLC purity figures, mass spec identity confirmation, endotoxin and sterility results, with the actual numbers listed. Most GLP-1 telehealth brands say “quality pharmacy” and stop there. FormBlends shows its work.
Cash pricing is higher than HealthRX, with semaglutide around $299 per vial and tirzepatide around $349. Shipping covers 47 states, not all 50. The platform also carries a wider peptide catalog covering recovery, longevity, and cognitive compounds, all under the same clinician model. That breadth is genuinely uncommon.
Pro: Published purity testing with real numbers, broader peptide options
Con: Higher price point than entry-tier competitors, and three states are excluded from shipping
4. Hims & Hers
Best for: People who prefer a major consumer brand and may have insurance
After the March 2026 Novo Nordisk settlement, Hims & Hers moved away from compounded GLP-1s and now focuses on branded medications. Injectable Wegovy runs about $299 a month through the platform, oral semaglutide about $249, and Zepbound about $399. With insurance and a manufacturer savings card, that can drop to nearly nothing for eligible patients. The app experience is polished and the platform is widely recognized, which matters to people who want a name they have seen advertised.
Pro: Branded FDA-approved meds, insurance pathway, well-known platform
Con: Cash prices are meaningfully higher than compounded alternatives; no longer an option if you specifically want compounded
5. Ro Body
Best for: Insured patients who want a prior-authorization team doing the legwork
Ro’s weight-loss program starts around $39 for the first month, then $74 to $149 a month after that, with branded medications billed separately. The prior-auth team is a real differentiator. Getting insurance to actually pay for a GLP-1 involves a lot of back-and-forth, and Ro has staff dedicated to that process. If you have decent insurance and just need someone to push the paperwork through, this setup makes sense.
Pro: Prior-auth support, accepts insurance for branded meds
Con: Medication cost is separate, so total monthly spend depends heavily on your coverage
Quick Comparison
| Provider | Cash Price (Sema) | Pharmacy Type | All 50 States |
| HealthRX | From $99/mo | Named 503A, lot-tracked | Yes |
| Mochi Health | ~$99/mo | Compounded | Not specified |
| FormBlends | ~$299/vial | Named 503A, purity-tested | 47 states |
| Hims & Hers | ~$249/mo (oral branded) | Branded/retail | Yes |
| Ro Body | Meds billed separately | Branded/retail | Yes |
My Take
For straight cash-pay value with verifiable pharmacy credentials, HealthRX is where I would start. FormBlends earns its spot for the purity-testing transparency and the peptide catalog breadth, at a higher price. Hims & Hers and Ro make more sense if you are running it through insurance. Mochi is worth considering if clinical monitoring depth matters to you more than price.
Common Questions
Is compounded semaglutide from a telehealth platform the same thing as Ozempic or Wegovy?
No. Compounded semaglutide contains the same active molecule but is not an FDA-approved finished drug product. It is mixed at a licensed 503A or 503B pharmacy to a prescription spec. Ozempic and Wegovy are manufactured by Novo Nordisk under full FDA approval, with standardized delivery devices and approved labeling.
Why does HealthRX list a specific pharmacy name when most competitors do not?
Named-pharmacy disclosure is a sign that a platform is willing to let you verify the source independently. Most telehealth GLP-1 brands describe their compounding partner in vague terms. HealthRX names Manifest Pharmacy in Greer, South Carolina, which means you can look up its LegitScript certification (cert 50087439) and USP-797 compliance status before ordering anything.
After the March 2026 Novo Nordisk settlement, can I still get compounded GLP-1s through Hims & Hers?
No. Hims & Hers moved away from compounded GLP-1s following that settlement and now focuses on branded medications like Wegovy and Zepbound. If you specifically want a compounded option, you would need to look at a different provider, such as HealthRX, Mochi, or FormBlends.
What does Mochi Health’s obesity-medicine specialist model actually mean in practice, compared to a standard async telehealth review?
Board-certified obesity-medicine physicians have completed additional training in the metabolic and physiological side of weight management, beyond general practice. In practice, that usually means more structured check-ins, closer attention to comorbidities like hypertension or insulin resistance, and dosing decisions made with that context in mind, rather than a one-time async questionnaire review.
How do I know if FormBlends’ published purity data is meaningful, or just a marketing document?
Look for specific test methods and numeric results, not just pass/fail labels. FormBlends lists HPLC purity figures, mass spec identity confirmation, and endotoxin and sterility results with actual numbers. That level of detail is harder to fabricate credibly and gives you something concrete to ask a pharmacist or physician about, which is the point.
Sources
- FDA warning letters to telehealth and compounding firms, early 2026 (FDA.gov)
- Novo Nordisk settlement announcement, March 9 2026 (public filings and press coverage)
- STEP 1 trial: Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide outcomes at 68 weeks)
- SURMOUNT-1 trial: Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide outcomes at 72 weeks)
- LegitScript pharmacy certification registry (LegitScript.com)
- Hims & Hers investor communications and platform pricing pages, 2026
- Ro pricing disclosures, public website
- Mochi Health public pricing page
